AbbVie (ABBV) Income from Non-Controlling Interests (2020 - 2026)

AbbVie (ABBV) reported Income from Non-Controlling Interests of $2.0 million for Q1 2026, down 33.33% year-over-year from $3.0 million in Q1 2025, and up 300.0% quarter-over-quarter from -$1.0 million in Q4 2025.

AbbVie (ABBV) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends

AbbVie (ABBV) has 7 years of Income from Non-Controlling Interests data on file, last reported at $2.0 million in Q1 2026.

  • Income from Non-Controlling Interests for Q1 2026 came in at $2.0 million, down 33.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 million (down 25.0% YoY), and the FY2025 annual result was $7.0 million, down 12.5% from the prior year.
  • Income from Non-Controlling Interests advanced to $2.0 million in Q1 2026 per ABBV's latest filing, from -$1.0 million in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at $4.0 million in Q2 2022 and troughed at -$1.0 million in Q4 2022.
  • A 5-year average of $2.1 million and a median of $3.0 million in 2022 frame the typical range for Income from Non-Controlling Interests.
  • The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests plunged 200.0% in 2022, then soared 300.0% in 2023.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at -$1.0 million in 2022, then soared by 300.0% to $2.0 million in 2023, then sank by 150.0% to -$1.0 million in 2024, then changed by 0.0% to -$1.0 million in 2025, then soared by 300.0% to $2.0 million in 2026.
  • Business Quant data shows ABBV's Income from Non-Controlling Interests at $2.0 million in Q1 2026, -$1.0 million in Q4 2025, and $2.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn 2.48 Bn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn -
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn -
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn 2.00 Mn
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn -3.00 Mn
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn -
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn -
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn 8.00 Mn
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn 1.00 Mn
10 Novartis Ag 112.59 Bn 111.90 Bn - 415.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.00 Mn
Dec 31, 2025 -1.00 Mn
Sep 30, 2025 2.00 Mn
Jun 30, 2025 3.00 Mn
Mar 31, 2025 3.00 Mn
Dec 31, 2024 -1.00 Mn
Sep 30, 2024 3.00 Mn
Jun 30, 2024 3.00 Mn
Mar 31, 2024 3.00 Mn
Dec 31, 2023 2.00 Mn
Sep 30, 2023 3.00 Mn
Jun 30, 2023 3.00 Mn
Mar 31, 2023 2.00 Mn
Dec 31, 2022 -1.00 Mn
Sep 30, 2022 3.00 Mn
Jun 30, 2022 4.00 Mn
Mar 31, 2022 3.00 Mn
Dec 31, 2021 1.00 Mn
Sep 30, 2021 1.00 Mn
Jun 30, 2021 3.00 Mn